A new daily medication called daraxonrasib has emerged as a promising treatment for advanced pancreatic cancer, with early trials showing significant reductions in tumour size for a subset of patients. The drug, which targets specific genetic mutations driving the disease, represents what experts describe as a major breakthrough for one of the most difficult cancers to treat effectively.
In recent trials involving 61 individuals with advanced pancreatic cancer that had spread to other parts of the body, the treatment demonstrated notable efficacy. Tumours ceased growing in 90% of participants, while more than 60% experienced a reduction in tumour size. Approximately 8% of the patients, or one in twelve, saw their cancer become undetectable on CT scans following the administration of daraxonrasib combined with chemotherapy.
Dr Sam Godfrey from Cancer Research UK described the findings as “the biggest leap forward in decades.” He noted that the new drug has successfully targeted mutations that were previously considered impossible to drug. Although most patients with advanced disease historically survive only months, the trial followed participants for an average of a year and a half, with some showing no signs of cancer return during this period.
Dr Wungki Park of Memorial Sloan Kettering Cancer Center stated that the results indicate not only higher tumour response rates but also deeper responses and a near-doubling of disease control duration. While these findings are encouraging for longer survival, medical professionals caution that longer studies are required to determine if remission is sustained over time. Daraxonrasib is a KRAS inhibitor already approved in the United States, and researchers hope its success in pancreatic cancer could extend to other malignancies such as lung and ovarian cancers, which share similar genetic mutations.
In Britain, approximately 11,500 people are diagnosed with pancreatic cancer annually, resulting in around 10,200 deaths. The disease remains notoriously hard to treat, often characterized by symptoms including jaundice, unexplained weight loss, and fatigue.
Sounds amazing, but remember these patients were still on chemo. We need to see standalone results soon.
Targeting KRAS is huge news. Hopefully, researchers can adapt this for other cancers like lung or ovarian.
Eight percent is still very small. We need much larger trials before I can call this a cure.
I can’t believe this is actually happening. My uncle lost his battle with this disease just last year.